Ionis Pharmaceuticals (IONS) reported $944M in revenue for fiscal 2025, +33.8% year on year. That ranks #1813 by revenue among 2853 SEC filers and #165 in Healthcare. It posted a net loss of −$381M for the same year. Revenue has grown 17.5% a year on average since 2011 ($99.1M then). The fiscal 2025 balance sheet shows $3.5B in total assets, $372M in cash and $1.3B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $944M | +33.8% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$382M | +$93.4M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$381M | +$72.5M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$269M | +$232M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $51.4M | +13.6% | FY20252025-12-31 |
| Total assetsAssets | $3.5B | +17.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $489M | −16.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $372M | +53.8% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $1.3B | +10.4% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $246M | −$92.5M | Open → |
| Q2 20262026-06-30 | $268M | −$115M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Ionis Pharmaceuticals Inc
- Ticker
- IONS
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000874015
Filings
- 10-QJul 29, 2026Open filing →
- 10-QApr 29, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Guardant HealthGH | $982M | −$416M |
| Madrigal PharmaceuticalsMDGL | $958M | −$288M |
| Pennant GroupPNTG | $948M | $29.6M |
| Ionis PharmaceuticalsIONS | $944M | −$381M |
| Usana Health SciencesUSNA | $925M | $10.8M |
| Tilray BrandsTLRY | $915M | −$121M |
| Inspire Medical SystemsINSP | $912M | $145M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ionis Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/ionis-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ionis Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/ionis-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-ionis-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Ionis Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ionis-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000874015-26-000115 · February 26, 2026
{{cite web |title=Ionis Pharmaceuticals — Key figures — 10-K (0000874015-26-000115) |url=https://www.sec.gov/Archives/edgar/data/874015/000087401526000115/form10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.